SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019)

Dómine Gómez, Manuel|||0000-0003-1634-9832; Moran Bueno, Teresa|||0000-0001-9172-0035; Isla, Dolores|||0000-0002-2483-198X; Martí, J.L.; Sullivan, Ivana|||0000-0002-0434-3436; Provencio Pulla, Mariano|||0000-0001-6315-7919; Olmedo García, María Eugenia|||0000-0002-0643-493X; Ponce Aix, Santiago|||0000-0002-2289-4709; Blasco Cordellat, Ana|||0000-0001-5889-0382; Cobo, Manuel|||0000-0003-3402-1144

SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019)

Small-cell lung cancer (SCLC) accounts for 15% of lung cancers. Only one-third of patients are diagnosed at limited stage. The median survival remains to be around 15-20 months without significative changes in the strategies of treatment for many years. In stage I and IIA, the standard treatment is...

Descripción completa

Detalles Bibliográficos
Autores:	Dómine Gómez, Manuel\|\|\|0000-0003-1634-9832, Moran Bueno, Teresa\|\|\|0000-0001-9172-0035, Isla, Dolores\|\|\|0000-0002-2483-198X, Martí, J.L., Sullivan, Ivana\|\|\|0000-0002-0434-3436, Provencio Pulla, Mariano\|\|\|0000-0001-6315-7919, Olmedo García, María Eugenia\|\|\|0000-0002-0643-493X, Ponce Aix, Santiago\|\|\|0000-0002-2289-4709, Blasco Cordellat, Ana\|\|\|0000-0001-5889-0382, Cobo, Manuel\|\|\|0000-0003-3402-1144
Tipo de recurso:	artículo
Fecha de publicación:	2020
País:	España
Institución:	Universitat Autònoma de Barcelona
Repositorio:	Dipòsit Digital de Documents de la UAB
Idioma:	inglés
OAI Identifier:	oai:ddd.uab.cat:283561
Acceso en línea:	https://ddd.uab.cat/record/283561 https://dx.doi.org/urn:doi:10.1007/s12094-020-02295-w
Access Level:	acceso abierto
Palabra clave:	Chemotherapy Immunotherapy Radiotherapy SCLC

id	ES_209aaf3f5e3dbdba10c4dfcf89b10d6e
oai_identifier_str	oai:ddd.uab.cat:283561
network_acronym_str	ES
network_name_str	España
repository_id_str
spelling	SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019)Dómine Gómez, Manuel\|\|\|0000-0003-1634-9832Moran Bueno, Teresa\|\|\|0000-0001-9172-0035Isla, Dolores\|\|\|0000-0002-2483-198XMartí, J.L.Sullivan, Ivana\|\|\|0000-0002-0434-3436Provencio Pulla, Mariano\|\|\|0000-0001-6315-7919Olmedo García, María Eugenia\|\|\|0000-0002-0643-493XPonce Aix, Santiago\|\|\|0000-0002-2289-4709Blasco Cordellat, Ana\|\|\|0000-0001-5889-0382Cobo, Manuel\|\|\|0000-0003-3402-1144ChemotherapyImmunotherapyRadiotherapySCLCSmall-cell lung cancer (SCLC) accounts for 15% of lung cancers. Only one-third of patients are diagnosed at limited stage. The median survival remains to be around 15-20 months without significative changes in the strategies of treatment for many years. In stage I and IIA, the standard treatment is the surgery followed by adjuvant therapy with platinum-etoposide. In stage IIB-IIIC, the recommended treatment is early concurrent chemotherapy with platinum-etoposide plus thoracic radiotherapy followed by prophylactic cranial irradiation in patients without progression. However, in the extensive stage, significant advances have been observed adding immunotherapy to platinum-etoposide chemotherapy to obtain a significant increase in overall survival, constituting the new recommended standard of care. In the second-line treatment, topotecan remains as the standard treatment. Reinduction with platinum-etoposide is the recommended regimen in patients with sensitive relapse (≥ 3 months) and new drugs such as lurbinectedin and immunotherapy are new treatment options. New biomarkers and new clinical trials designed according to the new classification of SCLC subtypes defined by distinct gene expression profiles are necessary.Universitat Autònoma de Barcelona 22020-01-0120202020-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/283561https://dx.doi.org/urn:doi:10.1007/s12094-020-02295-wreponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2835612026-06-06T12:50:31Z
dc.title.none.fl_str_mv	SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019)
title	SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019)
spellingShingle	SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019) Dómine Gómez, Manuel\|\|\|0000-0003-1634-9832 Chemotherapy Immunotherapy Radiotherapy SCLC
title_short	SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019)
title_full	SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019)
title_fullStr	SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019)
title_full_unstemmed	SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019)
title_sort	SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019)
dc.creator.none.fl_str_mv	Dómine Gómez, Manuel\|\|\|0000-0003-1634-9832 Moran Bueno, Teresa\|\|\|0000-0001-9172-0035 Isla, Dolores\|\|\|0000-0002-2483-198X Martí, J.L. Sullivan, Ivana\|\|\|0000-0002-0434-3436 Provencio Pulla, Mariano\|\|\|0000-0001-6315-7919 Olmedo García, María Eugenia\|\|\|0000-0002-0643-493X Ponce Aix, Santiago\|\|\|0000-0002-2289-4709 Blasco Cordellat, Ana\|\|\|0000-0001-5889-0382 Cobo, Manuel\|\|\|0000-0003-3402-1144
author	Dómine Gómez, Manuel\|\|\|0000-0003-1634-9832
author_facet	Dómine Gómez, Manuel\|\|\|0000-0003-1634-9832 Moran Bueno, Teresa\|\|\|0000-0001-9172-0035 Isla, Dolores\|\|\|0000-0002-2483-198X Martí, J.L. Sullivan, Ivana\|\|\|0000-0002-0434-3436 Provencio Pulla, Mariano\|\|\|0000-0001-6315-7919 Olmedo García, María Eugenia\|\|\|0000-0002-0643-493X Ponce Aix, Santiago\|\|\|0000-0002-2289-4709 Blasco Cordellat, Ana\|\|\|0000-0001-5889-0382 Cobo, Manuel\|\|\|0000-0003-3402-1144
author_role	author
author2	Moran Bueno, Teresa\|\|\|0000-0001-9172-0035 Isla, Dolores\|\|\|0000-0002-2483-198X Martí, J.L. Sullivan, Ivana\|\|\|0000-0002-0434-3436 Provencio Pulla, Mariano\|\|\|0000-0001-6315-7919 Olmedo García, María Eugenia\|\|\|0000-0002-0643-493X Ponce Aix, Santiago\|\|\|0000-0002-2289-4709 Blasco Cordellat, Ana\|\|\|0000-0001-5889-0382 Cobo, Manuel\|\|\|0000-0003-3402-1144
author2_role	author author author author author author author author author
dc.contributor.none.fl_str_mv	Universitat Autònoma de Barcelona
dc.subject.none.fl_str_mv	Chemotherapy Immunotherapy Radiotherapy SCLC
topic	Chemotherapy Immunotherapy Radiotherapy SCLC
description	Small-cell lung cancer (SCLC) accounts for 15% of lung cancers. Only one-third of patients are diagnosed at limited stage. The median survival remains to be around 15-20 months without significative changes in the strategies of treatment for many years. In stage I and IIA, the standard treatment is the surgery followed by adjuvant therapy with platinum-etoposide. In stage IIB-IIIC, the recommended treatment is early concurrent chemotherapy with platinum-etoposide plus thoracic radiotherapy followed by prophylactic cranial irradiation in patients without progression. However, in the extensive stage, significant advances have been observed adding immunotherapy to platinum-etoposide chemotherapy to obtain a significant increase in overall survival, constituting the new recommended standard of care. In the second-line treatment, topotecan remains as the standard treatment. Reinduction with platinum-etoposide is the recommended regimen in patients with sensitive relapse (≥ 3 months) and new drugs such as lurbinectedin and immunotherapy are new treatment options. New biomarkers and new clinical trials designed according to the new classification of SCLC subtypes defined by distinct gene expression profiles are necessary.
publishDate	2020
dc.date.none.fl_str_mv	2 2020-01-01 2020 2020-01-01
dc.type.none.fl_str_mv	Article http://purl.org/coar/resource_type/c_6501 VoR http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv	info:eu-repo/semantics/article
format	article
dc.identifier.none.fl_str_mv	https://ddd.uab.cat/record/283561 https://dx.doi.org/urn:doi:10.1007/s12094-020-02295-w
url	https://ddd.uab.cat/record/283561 https://dx.doi.org/urn:doi:10.1007/s12094-020-02295-w
dc.language.none.fl_str_mv	Inglés eng
language_invalid_str_mv	Inglés
language	eng
dc.rights.none.fl_str_mv	open access http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv	info:eu-repo/semantics/openAccess
rights_invalid_str_mv	open access http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv	openAccess
dc.format.none.fl_str_mv	application/pdf
dc.source.none.fl_str_mv	reponame:Dipòsit Digital de Documents de la UAB instname:Universitat Autònoma de Barcelona
instname_str	Universitat Autònoma de Barcelona
reponame_str	Dipòsit Digital de Documents de la UAB
collection	Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_	1869404468229963776
score	15.301603

SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019)

Similares en LA Referencia